EcoDrugPlus

40s Ribosomal Protein S26-Like

Ensembl ID : ENSPCTG00005017210
Gene Symbol: LOC102995087
3 Cross references
167 Possible Orthologues:

40s Ribosomal Protein S4, X Isoform-Like

Ensembl ID : ENSPCTG00005001312
Gene Symbol: LOC102986540
3 Cross references
155 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSPCTG00005011540
Gene Symbol: HTR1A
3 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSPCTG00005013942
Gene Symbol: HTR1E
3 Cross references
155 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSPCTG00005017483
Gene Symbol: HTR1F
3 Cross references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSPCTG00005017473
Gene Symbol: HTR2B
1 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSPCTG00005013724
Gene Symbol: HTR3A
1 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSPCTG00005020240
Gene Symbol: HTR3B
1 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPCTG00005003439
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPCTG00005007776
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSPCTG00005015113
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPCTG00005020889
Gene Symbol: HTR7
1 Cross references
219 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).